Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The Z ...

QIAGEN N.V. (QGEN) has announced plans to move its QIAstat-Dx operations to a new site in Esplugues de Llobregat as part of a multi-year investment to strengthen this business. Slated to open in early 2026, the new site builds on the long-standing presence of the company in the Barcelona area and will cover the entire value chain for the QIAstat-Dx system.The site will include teams such as Research & Development (R&D), Manufacturing, Sales, Marketing, Quality Assurance and Regulatory Affairs. Additionally, ...

Company Developments - QIAGEN N.V. has launched two new tools for designing and ordering custom solutions for microbial analysis, specifically targeting bacterial, fungal, and viral pathogens [1][5] - The new tools include a Custom dPCR Microbial Assays design tool and the QIAseq xHYB Custom Microbial Panels, enhancing the capabilities for researchers to customize assays for the QIAcuity digital PCR system and third-party NGS systems [5][6] - The new products expand the applicability of nanoplate dPCR to various microbial targets, including wastewater testing, food production, and human pathogen analysis [7] Market Performance - Following the announcement of the new tools, QGEN's share price fell by 5.2% to $41.47 in after-market trading [3] - QIAGEN currently has a market capitalization of $9.72 billion and has delivered an average earnings surprise of 3.52% over the last four quarters [4] Industry Prospects - The global digital PCR market was valued at $678.1 million in 2023 and is projected to grow to $3.3 billion by 2034, with a compound annual growth rate (CAGR) of 15.7% [8] - Key drivers for market growth include the increasing adoption of personalized medicine and advancements in technology [8] Recent Product Additions - In September, QIAGEN added over 100 validated QIAcuity digital PCR assays for various applications, including cancer research and infectious disease surveillance [10] - These new assays are designed to meet high standards of quality, multiplexing capabilities, customization, precision, and sensitivity [10] Stock Performance - Over the past year, QGEN's shares have increased by 2.9%, slightly underperforming the industry average growth of 3% [11]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are ...

QIAGEN's (QGEN) business is expected to get a boost from its growing molecular diagnostic market, expanded test menu and growth-driving strategic collaborations. Yet, the company faces a challenging macro environment. An intense competitive environment and exchange rate fluctuations may dent the results of operations. The stock carries a Zacks Rank #3 (Hold) at present.Factors Driving QGEN StockMolecular testing is the most dynamic segment of the global in vitro diagnostics market. QIAGEN offers one of the ...

Company Performance - Qiagen's total revenue for the quarter ending September 2024 was $501.87 million, a 5.5% year-over-year increase [4] - Asia Pacific, Japan, and Rest of World contributed $75.06 million (14.96% of total revenue), a -2.51% surprise compared to the expected $76.99 million [5] - Europe, Middle East, and Africa contributed $158.18 million (31.52% of total revenue), a -0.58% surprise compared to the expected $159.11 million [6] Revenue Projections - Wall Street analysts project Qiagen's revenue for the ongoing fiscal quarter to be $522.77 million, a 2.7% increase from the year-ago quarter [7] - Asia Pacific, Japan, and Rest of World are expected to contribute 15.6% ($81.38 million) and Europe, Middle East, and Africa 32.8% ($171.69 million) to the total revenue [7] - For the entire year, Qiagen's total revenue is forecasted to be $1.97 billion, a 0.3% improvement from the previous year [8] - Asia Pacific, Japan, and Rest of World are expected to contribute 15.5% ($306.3 million) and Europe, Middle East, and Africa 32.6% ($642.48 million) to the total revenue [8] Stock Performance - Over the past month, Qiagen's stock has declined by 0.4%, while the Zacks S&P 500 composite has increased by 4.4% [13] - The Zacks Medical sector, Qiagen's industry group, has declined by 1.4% over the same period [13] - Over the past three months, Qiagen's stock price has declined by 6.3%, while the S&P 500 index has risen by 13.1% [13] - The broader sector has declined by 2% during this interval [13] Market Context - The global economy's deep interlinkage makes a company's engagement with international markets critical for financial success and growth [2] - International market involvement serves as insurance against domestic economic downturns and enables engagement with faster-growing economies [3] - Qiagen's reliance on foreign markets presents a mix of opportunities and challenges, making vigilant monitoring of international revenue movements essential for projecting the company's future direction [9]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.W ...

Exhibit 99.1 QIAGEN N.V. and Subsidiaries U.S. GAAP Quarterly Report for the Period Ended September 30, 2024 Table of Contents Condensed Consolidated Financial Statements 2 Condensed Consolidated Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023 4 Condensed Consolidated Statements of Income (Loss) (unaudited) for the three and nine months ended September 30, 2024 and 2023 5 Condensed Consolidated Statements of Comprehensive Income (unaudited) for the three and nine months ended Septe ...

Financial Data and Key Metrics - Q3 2024 sales reached $502 million, representing 6% growth at constant exchange rates (CER), exceeding the outlook of at least $495 million [5] - Adjusted diluted EPS was $0.57, $0.03 above the outlook of at least $0.55 [5] - Adjusted operating income margin improved by 3% to 29.6% of sales compared to Q3 2023 [7] - Free cash flow increased by 73% to $364 million in the first nine months of 2024 [7] - Full-year 2024 net sales outlook reaffirmed at $1.985 billion at CER, with adjusted EPS target increased to at least $2.19 at CER [7] Business Line Performance - Diagnostic Solutions product group grew 10% CER, driven by strong demand for QuantiFERON TB test and QIAstat-Dx [5][10] - QIAstat-Dx sales grew 40% CER, with over 150 instrument placements in Q3 [5] - PCR product group saw double-digit CER growth in consumables, particularly for QIAcuity digital PCR system [10] - Genomics NGS product group sales remained unchanged compared to Q3 2023 [10] - Digital Insights business declined at a low single-digit CER rate due to the transition to SaaS subscription contracts [11] Regional Performance - Europe, Middle East, and Africa (EMEA) region sales rose 8% CER, with strong performance in France and Italy [11] - Americas sales grew 6% CER, driven by solid consumables growth offsetting lower instrument sales [11] - Asia Pacific and Japan region sales declined 2% CER, with China continuing to decline at a high single-digit rate [11] Strategic Direction and Industry Competition - QIAGEN is focusing on expanding its portfolio in liquid biopsy, precision medicine, and syndromic testing [6][15] - The company is transitioning its Digital Insights business to a SaaS model to align with customer preferences [11][44] - QIAGEN is investing in automation and new instrument launches to drive growth in sample technologies [9][50] - The company is leveraging partnerships with pharmaceutical companies like AstraZeneca and Eli Lilly to expand its precision medicine applications [6] Management Commentary on Operating Environment and Future Outlook - Management highlighted the challenging macro environment but expressed confidence in achieving 2024 targets due to strong recurring revenues [4][7] - The company is well-positioned for future growth, with a focus on delivering on its 2028 commitments [7][19] - Management emphasized the importance of innovation and efficiency in driving profitability and cash flow [7][12] Other Important Information - QIAGEN received FDA clearances for QIAstat panels, including the meningitis/encephalitis panel [5] - The company is discontinuing the NeuMoDx system by 2025, which is expected to improve margins [7][25] - QIAGEN raised $500 million through a convertible bond issuance to support strategic growth initiatives and repay debt [14] Q&A Session Summary Question: Sustainability of QuantiFERON growth - QuantiFERON growth is driven by the conversion from skin tests, partnerships with DiaSorin, and inclusion in national TB testing guidelines [22] - The company targets $600 million in QuantiFERON revenues by 2028, with a projected 6-7% CAGR [22] Question: Growth outlook for 2025 - Management expects continued growth in 2025, driven by momentum in QIAstat, QuantiFERON, and sample technologies [24] - Margin expansion is expected to continue, with NeuMoDx discontinuation contributing to improvements [25] Question: QIAstat placements and competitive dynamics - QIAstat placements exceeded 150 in Q3, with growth driven by menu expansion and competitive positioning in the US [27] - The company expects to achieve $200 million in QIAstat revenues by 2028 [27] Question: Capital deployment and M&A strategy - QIAGEN remains active in both share buybacks and M&A, with a focus on value creation and portfolio reinforcement [28] Question: Portfolio mix and growth drivers - The company is confident in its portfolio mix, with growth expected from QIAstat, QIAcuity, and Digital Insights [31][33] Question: Operating margin trajectory - Management sees potential for further margin improvement beyond the 31% target by 2028, driven by efficiency programs and R&D acceleration [34][41] Question: QDI business transition to SaaS - The shift to SaaS is a customer-driven trend, with no change in the volume of contracts or growth ambitions [44] Question: Sample prep performance and outlook - Sample technologies are expected to grow above market rates, driven by automation and new instrument launches [50] Question: NeuMoDx wind-down impact - NeuMoDx revenues are expected to phase out by H2 2025, with no significant contribution beyond Q2 2025 [52] Question: Instrument revenue outlook - Instrument revenue is expected to improve sequentially in Q4, though overall growth remains negative [55] Question: Liquid biopsy growth contribution - QIAGEN is a key enabler in the liquid biopsy market, with growth expected from oncology and other applications [56] Question: Impact of US election and tariffs - The company is monitoring potential policy changes but remains confident in its global presence and US market position [58][59]

Core Insights - QIAGEN N.V. reported third-quarter 2024 adjusted earnings per share (EPS) of 57 cents, a 14% increase from the previous year, exceeding the Zacks Consensus Estimate by 5.6% [1][2] - The company's quarterly net sales rose 5.5% year over year to $501.9 million, beating the Zacks Consensus Estimate by 2.3% [3] - QIAGEN's operational efficiency and market share gains were highlighted, despite margin contractions [13][14] Financial Performance - Adjusted gross profit decreased by 0.5% year over year to $316.1 million, with an adjusted gross margin of 62.9%, down 374 basis points [7][8] - Adjusted operating income increased by 1.2% year over year to $131 million, while the adjusted operating margin contracted to 26.1% [8] - The company ended the quarter with cash and short-term investments of $1.5 billion, up from $1.1 billion in the previous quarter [10] Segment Performance - Sample technologies revenues increased by 1% to $162 million, while diagnostic solutions revenues rose by 10% to $197 million [4] - PCR / Nucleic acid amplification revenues grew by 9% to $74 million, and genomics / NGS revenues remained stable at $55 million [5][6] - Other revenues decreased by 3% year over year to $14 million [6] Outlook - For the full year, QIAGEN expects net sales of at least $1.985 billion, with adjusted EPS projected at a minimum of $2.19 [11] - The company anticipates fourth-quarter net sales of at least $520 million and adjusted EPS of at least 60 cents [12] Strategic Developments - QIAGEN launched 100 new assays for the QIAcuity digital PCR system and expanded the QIAstat-Dx system's utility through partnerships with AstraZeneca and Eli Lilly [14]